Novo Nordisk's CEO took the Washington hot seat over Ozempic prices. 3 takeaways from his testimony
CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy benefit managers (PBMs) to look into the possibility of cutting list prices for the company’s popular diabetes and weight-loss drugs.
Looking at options history for Novo Nordisk NVO we detected 11 trades. If we consider the specifics of each trade, it is ...
O faturamento da farmacêutica dinamarquesa Novo Nordisk com o Ozempic e o Wegovy é tanto que as vendas acumuladas logo ...
Denmark Prime Minister Mette Frederiksen downplayed concerns that Ozempic maker Novo Nordisk (NVO), the Scandinavian nation’s ...
New public and private entrants are emerging to challenge the leading positions of Novo Nordisk NVO and Eli Lilly LLY in ...
Hi, it’s Bob in New York. I’ve been writing about drug costs for years, and Ozempic and Wegovy turn out to be in a unique ...
Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...
Lars Fruergaard Jørgensen, Novo Nordisk's CEO, says his company is working to expand manufacturing to meet the supply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback